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Abstract
Chronic lung infection by Pseudomonas aeruginosa is the major severe complication in cystic fibrosis (CF) patients, where P.
aeruginosa persists and grows in biofilms in the endobronchial mucus under hypoxic conditions. Numerous
polymorphonuclear leukocytes (PMNs) surround the biofilms and create local anoxia by consuming the majority of O2
for production of reactive oxygen species (ROS). We hypothesized that P. aeruginosa acquires energy for growth in
anaerobic endobronchial mucus by denitrification, which can be demonstrated by production of nitrous oxide (N2O), an
intermediate in the denitrification pathway. We measured N2O and O2 with electrochemical microsensors in 8 freshly
expectorated sputum samples from 7 CF patients with chronic P. aeruginosa infection. The concentrations of NO3
2 and
NO2
2 in sputum were estimated by the Griess reagent. We found a maximum median concentration of 41.8 mM N2O (range
1.4–157.9 mM N2O). The concentration of N2O in the sputum was higher below the oxygenated layers. In 4 samples the N2O
concentration increased during the initial 6 h of measurements before decreasing for approximately 6 h. Concomitantly, the
concentration of NO3
2 decreased in sputum during 24 hours of incubation. We demonstrate for the first time production of
N2O in clinical material from infected human airways indicating pathogenic metabolism based on denitrification. Therefore,
P. aeruginosa may acquire energy for growth by denitrification in anoxic endobronchial mucus in CF patients. Such ability
for anaerobic growth may be a hitherto ignored key aspect of chronic P. aeruginosa infections that can inform new
strategies for treatment and prevention.
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Introduction
Cystic fibrosis (CF) is an autosomal recessive disease. It is caused
by mutations in the cystic fibrosis trans-membrane conductance
regulator gene [1] affecting apical ion transport. In the lungs, the
defective ion transport results in endobronchial accumulation of
thick, viscous mucus that prevents mucociliar cleaning of the
lungs, and increases susceptibility to chronic respiratory infections
[2,3]. Pseudomonas aeruginosa is a Gram-negative, gamma proteo-
bacterium, which dominates chronic lung infections in CF patients
and is considered the most serious complication of CF [4,5]. The
chronic P. aeruginosa lung infection in CF patients is characterized
by presence of endobronchial biofilm aggregates surrounded by
numerous polymorphonuclear leukocytes (PMNs) [6,7]. Despite
the bactericidal activity of the PMNs and intensive antibiotic
therapy, these biofilms persist and grow in the endobronchial
mucus of CF patients over many years [7,8]. P. aeruginosa can
withstand the bactericidal activity of the PMNs by forming
biofilms of the protective mucoid phenotype [9] and by quorum
sensing (QS)-regulated production of leukolytic amounts of
rhamnolipid [10–13]. The summoned PMNs produce reactive
oxygen species (ROS) through a respiratory burst, which leads to
intense depletion of molecular oxygen (O2) [14], a common
feature of infected endobronchial mucus in CF [6]. Biofilm
formation may explain why P. aeruginosa survives the attacking
PMNs, but it is not known how P. aeruginosa acquires the energy
required for the observed growth in endobronchial secretions [8]
when O2 is absent. However, P. aeruginosa can grow anaerobically
with alternative electron acceptors or by arginine fermentation
[15], and it has been suggested that P. aeruginosa can respire by
denitrification in anoxic CF mucus utilizing nitrate (NO3
2) and
nitrite (NO2
2), which are both present in sufficient amounts
[15,16]. Although the ability of P. aeruginosa to utilize reduction of
NOx for anaerobic respiration is well known [17], denitrification
in mucus and persistent biofilms present in the airways of CF
patients remains to be demonstrated. Since N2O is a natural
intermediate belonging to the gases defining denitrification [17],
we used electrochemical microsensors [18] to measure O2 and
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N2O concentration gradients at high spatio-temporal resolution in
freshly expectorated sputum from CF patients with chronic P.
aeruginosa lung infection.
Further evidence for denitrification was obtained from nitrate
(NO3
2) and nitrite (NO2
2) turnover measurements in the sputum
samples. These measurements provided important new insights to
the micro-environmental conditions and chemical dynamics
associated with persistent P. aeruginosa lung infections in CF
patients and indicate that nitrogen compounds can play an
important role in the interaction between pathogenic bacteria and
an active immune response.
Results
N2O and O2 in sputum from CF patients with chronic P.
aeruginosa lung infection
Representative measurements of O2 and N2O in freshly
expectorated sputum were acquired with O2- and N2O micro-
sensors (Fig 1A). Measurements of O2- and N2O profiles in
expectorated sputum from a CF patient with chronic P. aeruginosa
lung infection showed the distribution of an upper oxygenated
zone and a lower anoxic zone. The N2O profile reached the
maximal concentration of N2O in the lower anoxic part of the
sputum sample, suggesting that denitrification is mainly confined
to the anoxic zone. A slow decline of O2 was apparently detected
above the sputum surface. This may be because the position of the
sputum surface was estimated by visual inspection, which is
associated with uncertainty due to small amounts of heterogeneous
saliva (Fig 1B).
Sputum is composed of heterogeneously distributed bacterial
aggregates surrounded by PMNs consuming O2, and this
respiratory burst creates local anoxic microenvironments in the
sputum [14]. The metabolic mechanisms are thus compartmen-
talized according to the availability of O2 with an oxygenated
zone, wherein the majority of O2 is reduced to superoxide by the
summoned PMNs, and an anoxic zone, where P. aeruginosa can
utilize nitrate as electron acceptor during oxidative phosphoryla-
tion (Fig. 1C).
NO3
2 and NO2
2 in sputum from CF patients with chronic
P. aeruginosa lung infection
NO3
2 and NO2
2 concentrations in sputum samples were
measured before N2O profiling and 1 day later (Fig 2). The
concentration of NO3
2 was significantly higher immediately
before N2O profiling as compared to 1 and 2 days after incubation
indicating NO3
2 depletion due to ongoing denitrification (Fig 2A,
B). The NO2
2 concentration was not changed significantly after
one day (Fig 2C), but by including additional measurements of the
NO2
2 concentration in 7 sputum samples a significantly decreased
NO2
2 concentration was detected (Fig 2D).
Distribution of N2O in sputum from CF patients with
chronic P. aeruginosa lung infection
Vertical profiles of O2 in sputum samples showed depletion of
O2, indicating the formation of anoxic zones below a mean depth
of 3.1 mm (SD = 3.0 mm) from the sputum surface (Fig 3A)
suggesting that the average depth of O2 penetration of ,3 mm. A
higher concentration of N2O was observed in the anoxic zone as
compared to the oxic zone (p,0.026, n = 8) (Fig 3B). To verify
that N2O is related to P. aeruginosa we found significantly less N2O
in three control sputum samples from 1 CF patient and from 2
Figure 1. Microsensor measurements of chemical gradients in sputum. (A) Close up of a sputum sample from a cystic fibrosis patient with
chronic P. aeruginosa lung infection with an inserted microsensor. (B) Representative microprofiles of N2O and O2 in a CF sputum sample. O2 profiles
are shown as the mean and SD of three microprofiles recorded in the beginning of the experiment and did not change significantly throughout the
experimental period, while the N2O profile represents the maximal N2O levels measured about 6–7 h after beginning. (C) A schematic model of the
involved PMN and biofilm processes in CF sputum explaining the microprofiles.
doi:10.1371/journal.pone.0084353.g001
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primary ciliary dyskinesia (PCD) patients without detectable P.
aeruginosa (p,0.030).
Dynamics of N2O in sputum from a CF patient with
chronic P. aeruginosa lung infection
Figure 4 displays time series of representative N2O profiles
measured vertically through a sputum sample. The distribution of
O2 is displayed at 0 hr. During the initial measuring period, N2O
accumulated in the anoxic zone reaching a maximum concentra-
tion of 160 mM after 6.5 h incubation, which indicates ongoing
production of N2O. Within the subsequent 4 hours the accumu-
lated N2O decreased indicating consumption through reduction to
N2.
Rates of N2O production and consumption in sputum
samples
Measurements of the N2O concentration dynamics over time in
particular depths of a sputum sample showed an initial build-up of
N2O in layers below 7 mm (Fig. 5). In each layer, the slope of the
net production curves was quasi-linear after ,180 min indicating
a constant production of N2O related to the particular layer and
therefore that N2O originates from immobile sources such as
biofilm. The production ceased about 6–7 h after start of the
sample incubation, and was then followed by a net consumption of
N2O over the following 4–5 h leading to N2O depletion in the
sputum sample after ,10–12 hours. In 4 sputum samples it was
possible to estimate N2O production and consumption rates
(Table 1) and N2O flux rates and cumulated emission (Figure 6)
from measurements of such dynamic N2O concentration micro-
gradients. A substantial initial N2O concentration was observed in
the anaerobic zone of the remaining 4 assayed sputum samples. In
these samples the N2O concentration decreased steadily during
incubation.
Discussion
The ability of microorganisms to exploit a wide range of
electron acceptors for ATP generation by oxidative phosphoryla-
tion provides metabolic flexibility in transient environments as
these organisms inhabit a variety of habitats ranging from soils,
sediments to aquatic environments [19]. Even though several
human pathogens, including P. aeruginosa, are equipped with the
genetic setup for denitrification [20–22] including nitric oxide
reductase (NOR) [22], we present the very first observations of
N2O production in clinical material from infected human airways
demonstrating pathogenic metabolism based on denitrification.
These data indicate that denitrification may serve as an alternative
metabolic pathway allowing P. aeruginosa to thrive in O2 depleted
micro niches in the airways of CF patients. Besides our study,
denitrification in humans has previously been demonstrated in
human dental plaque [23] and has been related to infections of the
gastrointestinal tract by the increased concentration of N2O in
exhaled breath from patients after oral intake of NO3
2 [24].
Seminal observations of O2 depletion and the presence of OprF
porin, which is involved in NO3
2 and NO2
2 diffusion, in habitats
of P. aeruginosa during chronic lung infection of CF patients
provided initial evidence for anaerobic respiration by denitrifica-
tion [6,16]. To demonstrate denitrification we have included CF
patients, who suffered from chronic P. aeruginosa infection in the
endobronchial mucus as detected by routine culturing. We
revealed a depletion of O2 in CF sputum samples, which is in
accordance with the steep O2 gradients in endobronchial CF
mucus [6] and due to O2 consumption by activated PMNs for
generation of ROS [14]. Our O2 measurements in sputum
confirmed the presence of O2 concentration gradients reaching
anoxia ,3 mm below the sputum surface.
The depletion of O2 for microbial respiration in infected
endobronchial CF mucus has motivated the present and several
other studies of anaerobic metabolism by P. aeruginosa based on
denitrification during chronic lung infection in CF. We demon-
strated N2O production and consumption in the sputum samples
indicating the presence of active NOR and nitrous oxide reductase
(N2OR) for the reduction of nitric oxide (NON) and N2O [17].
Previously, NOR has been isolated from P. aeruginosa [25], the
genes (norCB) have been sequenced [26] and functional NOR has
been observed in clinical strains of P. aeruginosa by consumption of
NON [27].
In our study, the initial phase of N2O production in the sputum
samples was followed by a period of net N2O consumption
suggesting a depletion of NON and a concomitant reduction of
N2O to N2 by N2OR. The N2O consumption is in agreement with
the demonstration of N2OR activity and the identification of the
nos genes in P. aeruginosa [28] as well as the induced genes for a
N2OR precursor in clinical isolates [29].
Our demonstration of significant N2O production in sputum
indicates ample presence of NO3
2 and NO2
2 that serve as
electron acceptors for the denitrification pathway. We found high
levels of NO3
2 and NO2
2 in the sputum, which are in agreement
with previous findings [30–32]. It has been proposed that NO3
2
Figure 2. Consumption of NO32 and NO22 in sputum. (A, B)
NO3
2 concentration in sputum samples from cystic fibrosis patients
with chronic P. aeruginosa lung infection. (C, D) NO2
2 concentration in
sputum samples from cystic fibrosis patients with chronic P. aeruginosa
lung infection. Samples were collected immediately after expectoration
and after 1 (n = 20) and 2 days (n = 7) of incubation. Data were analyzed
by Wilcoxon signed rank test.
doi:10.1371/journal.pone.0084353.g002
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and NO2
2 in CF sputum originates from the rapid reaction
between superoxide (O2
-) and NON [15]. In this regard, we suggest
the summoned activated PMNs [14] as a major source of O2
-,
while NON, which is present in CF exhaled breath [33,34], may be
produced by a variety of cells in the lungs. In fact, inhalation of
NON or incubation of sputum samples with NON resulted in
elevated levels of NO3
2 and NO2
2 in sputum from CF patients
[35]. In addition, ongoing activity of the patients nitric oxide
synthases was evidenced by the increased exhaled NON from
infected CF patients following supplementation with the substrate
L-arginine [36,37].
As a consequence of our demonstration of N2O production, we
expected a consumption of the precursors NO3
2 and NO2
2.
Accordingly, NO3
2 was depleted in the sputum after incubation
for 1 day, which likely is due to the membrane-bound nitrate
reductase of P. aeruginosa [29]. NO3
2 consumption may also
accompany assimilatory denitrification and ammonification re-
sulting in the formation of ammonia (NH4
+) [17], which has been
detected in CF sputum [27]. However, assimilatory denitrification
and ammonification does not involve production of N2O
[17,38,39] and NH4
+ is also produced by several human cell
types [40]. The concentration of NO2
2 was not changed during 1
day of incubation, but after 2 days of incubation the concentration
of NO2
2 in the sputum was decreased significantly. This indicates
that the production of NON from NO2
2 is slower than the
generation of NO2
2 resulting from reduction of NO3
2. Indeed,
during reduction of NO3
2 transient accumulation of NO2
2 is
known from anaerobic cultures of P. aeruginosa growing by
denitrification [16,41,42].
A further verification of ongoing dissimilatory denitrification in
sputum is evident from the calculated rate of N2O production
(Fig. 6A), which easily can explain the depletion of NO3
2 during
incubation (Fig. 2A). The depletion of NO3
2 in the sputum
samples indicates that the NO3
2 in sputum samples is not replaced
by the reaction between O2
- and NO. This is possibly due to lack
of contributions from immigrating PMNs and the epithelia as
opposed to the conditions in the endobronchial mucus.
Since we calculated the rates of N2O production by assuming
linear changes between subsequent measurements in the begin-
ning of incubation, the estimates are likely to reflect the situation in
the endobronchial mucus, where reduced NO3
2 and NO2
2 is
continuously being replaced as indicated by the high NO3
2 and
NO2
2 content in fresh sputum. The estimated N2O production,
however, is calculated from the actual N2O content and does not
include the reduction of N2O to N2. Therefore, the actual rate of
denitrification may be higher than our estimates.
We found the highest concentration of N2O in the anoxic zone
of the confined sputum samples indicating higher rate of
denitrification without O2 as previously demonstrated [43].
Accordingly, we suggest that the low concentration of N2O found
in the oxygenated zone is mainly due to diffusion from the active
anoxic zone. Additionally, our estimate of the depth of the
oxygenated zone implies that the bronchi, with diameters ranging
from 0.8 to 13 mm [44,45], allow for numerous anoxic zones in
the endobronchial mucus of the lungs and confirms the in vivo
demonstration of O2 depletion in the endobronchial mucus [6].
Consequently, our results propose the existence of several zones
with N2O production in the anoxic endobronchial mucus of the
lungs of CF patients with chronic P. aeruginosa lung infection.
However, such in vivo production of N2O in CF patients still awaits
direct experimental confirmation.
The involvement of denitrification enzymes as terminal oxidases
that reduce nitrogen oxides in the highly branched respiratory
chain of P. aeruginosa may enable anaerobic growth in the presence
of nitrate or nitrite [19,46]. But the engagement of denitrification
in P. aeruginosa may also contribute to virulence as evidenced by the
finding of antibodies directed against components of denitrifica-
tion in CF patients with P. aeruginosa lung infection [16,47] and the
dependence on nitrite reductase for type III secretion [48]. In
anaerobic cultures, denitrification promotes growth of P. aeruginosa
[49], increases antibiotic tolerance of P. aeruginosa [50] and favors
maintenance of the virulent mucoid phenotype [30].
A particular contribution to the pathogenesis of chronic lung
infection in CF by NOR activity, is suggested by the induced in vivo
Figure 3. Distribution of O2 and N2O in sputum. (A) Depth of oxygenated zone in sputum samples from cystic fibrosis patients with chronic P.
eruginosa lung infection (n = 8). (B) Maximal N2O concentration in the oxic zone and anoxic zone in sputum samples from cystic fibrosis patients with
chronic P. aeruginosa lung infection (n = 8). Control sputum without detectable P. aeruginosa was obtained from two PCD patients and one CF
patient. Statistical analysis was performed by Student t-test.
doi:10.1371/journal.pone.0084353.g003
N2O Production in CF Sputum
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gene expression in clinical isolates [29] including the highly
virulent mucoid isolates [51]. In this respect, the reduction of NON
to N2O by active NOR may actually protect P. aeruginosa from the
bactericidal action of NON generated by the immune system. In
fact, NOR-deficient P. aeruginosa is more susceptible to NON
generated by macrophages [52] and less virulent during infection
of silkworm [53]. In addition, NOR activity increases the virulence
of several pathogens [54–56].
In conclusion, this study points to the presence of anoxic
microenvironments with strong spatio-temporal heterogeneity as
well as a possible stratification of metabolic processes in the biofilm
aggregates characteristic of chronic P. aeruginosa infections in the
airways of CF patients. Such structural and metabolic heteroge-
neity may be a characteristic trait ensuring persistent infection.
Indeed, spatio-temporal resolved measurements enabled the
demonstrated of N2O production in the anaerobic zones of freshly
expectorated sputum samples from CF patients with chronic P.
aeruginosa lung infection for the first time. Analysis of the N2O
production rates suggests ongoing generation of N2O in the lungs
of CF patients with chronic P. aeruginosa infection. N2O production
Figure 4. Generation and depletion of N2O in sputum. Spatio-temporal dynamics of N2O concentration profiles in a representative sputum
sample from a cystic fibrosis patient with chronic P. aeruginosa lung infection showing initial accumulation of N2O in the anoxic zone followed by
total depletion. The O2 concentration profile is shown as the mean and SD of three microprofiles recorded at the beginning of the experiment.
doi:10.1371/journal.pone.0084353.g004
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Figure 5. Rates of N2O production and consumption in sputum. Depth specific plots of N2O concentration vs. time at particular measuring
depths in the same sputum sample as displayed in Fig 4. Accumulation and thus net production of N2O in all depths was observed until
approximately 6 h, followed by net consumption of N2O presumably due to depletion of nitrate around 6 h.
doi:10.1371/journal.pone.0084353.g005
Table 1. N2O production, consumption, max emission, and cumulated emission in 4 CF sputum samples.
Net production rate Net consumption rate Max emission Cumulated emission
(nmol cm23min21) (nmol cm23min21) (nmol cm22 min21) (nmol cm22)
Median 0.47 20.39 5.0661025 1.0561022
Range 0.40–0.70 20.77–20.10 1.861025–6.7861025 3.9461023–1.4661022
doi:10.1371/journal.pone.0084353.t001
N2O Production in CF Sputum
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by P. aeruginosa in this environment is associated with anaerobic
growth, which can promote increased virulence and tolerance to
antibiotic, as well as contribute to evasion of the host response.
The chronic infected CF lung is in many ways a black box. By
using the presented approach to elucidate the essential metabolites
we may now open the black box and start mapping the micro-
environment of infection which may inspire new strategies for
prevention and treatment of chronic lung infections in CF.
Materials and Methods
Sputum Samples
As defined by the ‘‘Danish Act on Research Ethics Review of
Health Research Projects’’ Section 2 the project does not
constitute a health research project and was thus initiated without
approval from The Committees on Health Research Ethics in the
Capital Region of Denmark. Therefore, verbal informed consent
was obtained using waiver of documentation of consent. The study
was carried out on 21 anonymized samples of surplus expectorated
sputum from 21 CF patients and 2 PCD patients (Table 2).
Chronic P. aeruginosa infection was defined as the presence of P.
aeruginosa in the lower respiratory tract at each monthly culture for
.6 months, or for a shorter time in the presence of increased
antibody response to P. aeruginosa (.2 precipitating antibodies,
normal: 0–1) [57].
Microsensor Measurements of O2 and N2O. Each of 8
different sputum samples (1–2 ml) was added to a glass vial
(35612 mm) (Schuett Biotec, Germany) and allowed to settle for
about 10 min. The glass vials were positioned in a heated metal
rack, kept at 37uC. Vertical O2-concentration profiles were
recorded in the sputum with an amperometric O2 microsensor
(OX25, Unisense A/S, A˚rhus, Denmark) mounted in a motorized
PC-controlled profiling setup (MM33 and MC-232, Unisense A/
S). Subsequently, vertical N2O concentration profiles were
recorded at defined time intervals for up to 12 hours with an
amperometric N2O microsensor [18] (N2O-25, Unisense A/S)
mounted in the micromanipulator.
The microsensors (tip diameter 25 mm) were connected to a
picoammeter (PA2000, Unisense A/S) and positioned manually
onto the upper surface of the sputum sample. Profile measure-
ments were taken by movement of the sensor in vertical steps of
100 or 200 mm through the sputum sample. Positioning and data
acquisition were controlled by dedicated software (Sensortrace Pro
2.0, Unisense A/S). The software was set to wait 3 seconds for the
O2-microprofile and 5 seconds for the N2O-microprofile, before
actual measurement and subsequent movement of the sensors to
the next measuring depth. The interval between each cycle of
profile measurements was 10 seconds.
The O2-microsensor was linearly calibrated by measuring the
sensor signal in an alkaline sodium ascorbate solution (zero O2)
and in air saturated free phosphate buffered saline (PBS) at
experimental temperature and salinity. The O2 concentration in
air saturated water was determined from the known temperature
and salinity according to [58]. The N2O -microsensor was linearly
calibrated according to [18] by measuring sensor signals in N2O
free PBS at experimental temperature and salinity and in PBS with
sequential addition of a known volume of N2O saturated PBS up
Figure 6. Efflux and cumulated emission of N2O from sputum samples. (A) Estimated N2O efflux rates in sputum samples from cystic fibrosis
patients with chronic P. aeruginosa lung infection as calculated from N2O microprofiles (n = 4). (B) Cumulated N2O emission as calculated from N2O
microprofiles (n = 4). I, II, III and IV represents 4 different sputum samples.
doi:10.1371/journal.pone.0084353.g006
Table 2. Demographic data of the patients.
CF patients PCD patients
Infectious status
P. aeruginosa S. aureus H. influenzae
Number (male) 20 (10) 1 (1) 2 (0)
Age (years)* 39 (24–50) 17 32 (27–36)
Duration of chronic infection
(years)*, **
19 (4–38)
FEV1 (%)* 56 (23–96) 75 89 (70–109)
FVC (%)* 88 (46–139) 82 110 (95–125)
*Values are medians (range).
*Duration of chronic infection is only recorded for P. aeruginosa infections.
FEV1, forced expiratory volume in 1 s.
FVC, forced vital capacity.
doi:10.1371/journal.pone.0084353.t002
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to a final concentration of 100 mM N2O. The N2O concentration
in saturated PBS was determined according to [59].
NO3
2 and NO2
2 quantification. The concentration of
NO3
2 and NO2
2 in sputum was measured in 20 samples. From
each sputum sample, 0.1 ml was aspired with a syringe and was
immediately diluted 10x in PBS and stored at -20uC for later
analysis. The remaining sample was incubated in a glass vial at
37uC for 24 h before dilution 10x in PBS and storage at 220uC.
The NO3
2 and NO2
2 levels in the sputum were measured using
the Griess colorimetric reaction (no. 780001, Cayman Chemicals,
USA) according to the manufacturer’s recommendations. For this,
sputum samples were transferred to a 96 well microtiter plate.
NO2
2 concentration was estimated by addition of the Griess
Reagent for 10 minutes, whereby NO2
2 was converted into a
purple azo-compound, which was quantitated by the optical
density at 540–550 nm measured with an ELISA plate reader
(Thermo Scientific Multiskan EX, Thermo Fisher Scientific Inc,
BioImage, Denmark). Total NO3
2 and NO2
2 levels were
estimated by a two-step analysis process: The first step converted
NO3
2 to NO2
2 utilizing NO3
2 reductase. After incubation for
2 hours, the next step involved the addition of the Griess Reagent,
whereby NO2
2 was converted into a purple azo-compound. After
incubation with Griess Reagent for 10 minutes, the optical density
at 540–550 nm was measured with an ELISA plate reader
(Thermo Scientific Multiskan EX, Thermo Fisher Scientific Inc,
BioImage, Denmark). A NO3
2 standard curve was used for
determination of total NO3
2 and NO2
2 concentration, while a
NO2
2 standard curve was used for determination of NO2
2 alone.
The concentration of NO3
2 was calculated as the difference
between the NO3
2 concentration and the total NO3
2 and NO2
2
concentration.
Calculations of N2O production rates. The local N2O
fluxes in sputum samples were calculated from the measured N2O
concentration gradient in the uppermost oxic sputum layer. It was
assumed that no production or consumption of N2O occurred in
the presence of O2. The flux was calculated using a modified
version of Fick’s 1st law of diffusion [60], where the slope of the
profile in the sputum surface layer was calculated from the three
uppermost measured concentrations (measurement a, b and c):
J~0:5 {D
Ca{Cb
xa{xb
 
z0:5 {D
Cb{Cc
xb{xc
 
where J is the flux of N2O (nmol N2O cm
22 min21), D is the
molecular diffusion coefficient of N2O in water at 37uC
(2.7661025 cm2 s21) [61] and C is the concentration of N2O
(mmol liter21) at depth xn, where n = a, b or c denote 3 subsequent
depths of measurement. The cumulated N2O emission was
calculated by assuming linear changes between subsequent
measurements. Net production and net consumption rates of
N2O in particular sputum layers were calculated from the slopes of
linear increase and decrease of N2O concentration at particular
measuring depths in the sputum samples [62,63].
Statistical Analyses. Statistical significance was evaluated by
Wilcoxon Signed Rank Test and by Students T-test. A p value
,0.05 was considered statistically significant. The tests were
performed with Prism 4.0c (GraphPad Software, La Jolla,
California, USA).
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